Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
TEL AVIV, ISRAEL, Jan. 30, 2018 -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System (EPS) was successfully featured in a live case transmission at the Leipzig Interventional Course (LINC) 2018 on January 30th.
Dr. Antonio Micari and Dr. Fausto Castriota, vascular surgeons with Maria Cecilia Hospital, Cotignola, Italy, performed a live endovascular procedure entitled, “Symptomatic left internal carotid disease in a 79-year old woman,” featuring CGuard™ EPS that was transmitted real time to the congress.
Dr. Fausto Castriota commented, “We have now been using CGuard™ EPS in our routine practice since we were first introduced to it in May 2017 and felt it would be the right system for treating this patient and demonstrating CGuard™ EPS’ advantages. In this case, CGuard™ EPS performed perfectly, as expected. It will continue to be an important tool in the treatment paradigm for carotid artery disease as carotid artery stenting becomes an increasingly viable alternative to the surgical carotid artery endarderectomy procedure in Europe.”
“It is an honor to have our technology featured so prominently at this leading industry conference, especially by these two leading vascular surgeons,” commented James Barry, PhD, Chief Executive Officer of InspireMD. “LINC is one of the leading global forums on new products and methods in the field of vascular medicine, and brings together leading medical professionals from around the world. The fact that CGuard™ EPS was, once again, selected for live case transmission at this leading global conference is strong validation of the uptake we are experiencing with key opinion leaders.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Investor Contacts: InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 FREE Email: [email protected] Crescendo Communications, LLC David Waldman Phone: (212) 671-1021 Email: [email protected]
